Healthcare >> CEO Interviews >> October 23, 2015
A.J. Kazimi founded Cumberland Pharmaceuticals, Inc., in 1999 and has served as Chief Executive Officer and Chairman of the board of directors since its inception. Prior to forming Cumberland, he served as President and Chief Operating Officer of Therapeutic Antibodies Inc., a biopharmaceutical company. During his 11 years with the company, Mr. Kazimi oversaw operations in three countries and played a key role in the company’s product development strategies, licensing and distribution agreements, and the raising of more than $100 million through equity and debt financings, as well as its initial public offering. Earlier in his career, he worked at Brown-Forman Corporation, rising through a series of management positions. Mr. Kazimi previously served on the board of directors for the Nashville Health Care Council, an industry association representing the largest concentration of health care companies in the United States, and Aegis Toxicology Sciences Corporation, a federally certified forensic toxicology laboratory. He also serves as Chief Executive Officer of Cumberland Emerging Technologies, Inc. — CET. He holds a B.S. from the University of Notre Dame and an MBA from the Vanderbilt Owen Graduate School of Management. Profile
TWST: Could you provide a brief overview of your company and describe its business model if at all unique?
Mr. Kazimi: Cumberland is a specialty pharmaceutical